Specialty Pharma Journal Specialty, Precision & Technology
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Rock Ventures. Cedilla is leveraging a growing understanding of the principles that dictate protein stability …
Tag Archives: Third Rock Ventures
April, 2018
September, 2016
-
14 September
Third Rock Launches Relay Therapeutics to Create Breakthrough Medicines Based on Protein Motion
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Third Rock Ventures, LLC today announced the formation of Relay Therapeutics with $57 million in Series A financing, including participation from an affiliate of D. E. Shaw Research, LLC. Relay Therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion, with the aim of …
-
7 September
Horizon and Fulcrum Therapeutics Partner for Novel CRISPR-Based Target Discovery
Cambridge, UK, 6 September 2016: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), the world leader in the application of gene editing technologies, today announced a new collaboration with Fulcrum Therapeutics Inc., (“Fulcrum”), a US-based firm founded in July 2016 by Third Rock Ventures. The collaboration will utilize Horizon’s world-leading CRISPR-based …
April, 2015
-
23 April
Jounce Therapeutics Secures $56 Million to Advance Novel Immuno-Oncology Drugs
Two-year old biotech, Jounce Therapeutics Inc. announced that it has raised a $56 million Series B round, which will be used to develop new immuno-oncology drugs. Unlike many drugmakers designing therapies that make it harder for cancer to hide from the immune system, Jounce is studying the therapeutic potential of …